Abstract
Type 1 cannabinoid (CB1) receptors are expressed in high concentrations in the central nervous system, including the basal ganglia, and could have direct or indirect effects on motor behavior through modulation of dopaminergic, glutamatergic and GABA-ergic neurotransmission. Using the CB1 receptor radioligand [ 18F]MK-9470 and small-animal PET, we investigated for the first time in vivo cerebral changes in [ 18F]MK-9470 binding in the 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease (PD), parallel to dopamine transporter (DAT) imaging, tyrosine hydroxylase (TH) staining, and behavioral measurements. In the 6-OHDA model, relative [ 18F]MK-9470 PET binding decreased in the contralateral cerebellum (−9%, p < 0.0004) and caudate-putamen bilaterally (ipsilateral −8%, contralateral −7%; p = 0.001 and p < 0.0003, respectively). The number of TH + neurons in the substantia nigra was inversely correlated to CB1 receptor binding in the ipsilateral cerebellum (p = 1.10 −6). The behavioral outcome was positively related to regional CB1 receptor binding in the contralateral somatosensory cortex (p = 4.10 −6). In vivo [ 18F]MK-9470 PET imaging points to changes in endocannabinoid transmission, specifically for CB1 receptors in the 6-OHDA model of PD, with mainly involvement of the caudate-putamen, but also distant regions of the motor circuitry, including the cerebellum and somatosensory cortex.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
